Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Richard Beresis

Steven L Colletti

Amjad Ali

Donald W Graham

David A Claremon

Sander G Mills

Nigel J Liverton

Tesfaye Biftu

William H Parsons

James M Balkovec

Peter J Sinclair

James B Doherty

James R Tata

XiaoXia Qian

Christopher Francis Thompson

Richard Berger

Cameron James Smith

Dennis M Schmatz

Charles J McIntyre

Frederick Wong

Gool F Patel

Gui-Bai Liang

Dennis M Zaller

Joung L Goulet

Mark A Holmes

Helen M Armstrong

Xingfang Hong

Dennis D Feng

Ernest W Kovacs

Mark G Steiner

The present invention encompasses compounds of Formula (I) and Formula (II) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. 

Selective spirocyclic glucocorticoid receptor modulators

The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.

Selective non-steroidal glucocorticoid receptor modulators

Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis 

(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

Src kinase inhibitor compounds

Growing community of inventors

Matawan, NJ, United States of America

Richard Beresis